Develop Potent Methyltransferase Inhibitors to Target Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
开发有效的甲基转移酶抑制剂来治疗严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2)
基本信息
- 批准号:10175592
- 负责人:
- 金额:$ 41.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAffinityAntiviral AgentsBindingBiochemicalBiological AssayCOVID-19COVID-19 pandemicCell modelCellsCellular AssayCenters for Disease Control and Prevention (U.S.)Cessation of lifeChemicalsChinaClinicalClinical assessmentsCollectionComplexComputer AssistedCoronavirusCoronavirus InfectionsCrystallizationDNA SequenceDNA-Directed RNA PolymeraseDatabasesDevelopmentDisease OutbreaksDockingDrug TargetingEnzymesEscherichia coliEtiologyEventFamilyFutureGenomeHong KongHumanImmuneImmune systemInvestigational TherapiesLeadLifeLigand BindingMeasuresMethodsMethylationMethyltransferaseNeutral RedNickelNonstructural ProteinOutcomePathway interactionsPeptide HydrolasesPharmaceutical PreparationsPopulationPositioning AttributePreventionProteinsRNARNA CapsRNA VirusesRecombinantsReportingResearchResolutionRiboseRoentgen RaysSARS coronavirusSevere Acute Respiratory SyndromeSourceSpeedStainsStructureTestingTherapeuticTherapeutic AgentsUnited StatesValidationViralViral VaccinesVirulenceVirusVirus DiseasesVirus ReplicationWorkbasebetacoronaviruscombatdesigndrug discoveryeffective therapyenzyme mechanismexperienceexpression vectorin silicoin vivo Modelinhibitor/antagonistinnovationnovelnovel therapeuticspandemic diseasepathogenpre-clinical assessmentprotein complexscreeningsmall molecule librariestargeted treatmenttherapeutically effectiveviral RNAvirtual screening
项目摘要
The recently emerged coronavirus disease-2019 (COVID-19) that commenced in Wuhan China has spread
globally at an unprecedented speed. The etiological pathogen for this pandemic disease is a new, enveloped,
positive-sense, single-stranded RNA coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2). The genome of SARS-CoV-2 is evolutionarily related to the betacoronavirus that caused the SARS
outbreak in 2003. Currently there are no targeted effective therapeutics and no vaccines for the viral prevention.
In order to rapidly innovate effective medications for clinical curing of this viral infection, we are launching a drug
discovery campaign with combined team efforts to develop new therapeutic agents against COVID-19. We aim
to target the nonstructural protein 16 (nsp16) of SARS-CoV-2, the ribose 2′-O-methyltransferase enzyme (2′-O-
MTase) that is responsible for the formation of viral RNA cap-1 structure, the last step of the 5’-capping of the
coronavirus. The methylation mechanism is important for both viral replication and viral evasion by host immune
recognition. Thus, drugs targeting the 5’-capping pathway are ideal for eliminating the virulence of this pathogen.
The X-ray crystal structures of nsp16/nsp10 protein complex of SARS-CoV-2 have recently been resolved, which
showed a great structural similarity to the SARS-CoV nsp16/nsp10 complex structures. The availability of these
high-resolution structures provide the important structural basis for screening and design of nsp16 inhibitors. In
this project, we will combine computer-aided in silico screening, sensitive biochemical assays, and antiviral cell
assays to identify potent nsp16 inhibitors to combat this coronavirus. We will carry out structure-based high-
throughput virtual screening to rapidly discover effective inhibitors of the nsp16 2’-O-MTase. The top screening
hits will be subjected to biochemical screening against recombinant nsp16 enzyme of SARS-COV-2. Validated
nsp16 2’-O-MTase inhibitors will be tested for antiviral activity against SARS-CoV2 strains. The accomplishment
of this drug discovery campaign is to generate a novel avenue of experimental therapy against the existential
COVID-19 pandemic via inhibiting the 5’-capping pathway of the coronavirus.
始于武汉的新近出现的冠状病毒病-2019年(新冠肺炎)中国现已蔓延
在全球范围内以前所未有的速度。这种大流行疾病的病原体是一种新的、包膜的、
阳性,单链RNA冠状病毒,严重急性呼吸综合征冠状病毒2(SARS-
CoV-2)。SARS-CoV-2的基因组在进化上与引起SARS的贝塔冠状病毒有关
2003年暴发。目前还没有针对性的有效治疗方法,也没有预防病毒的疫苗。
为了迅速创新治疗这种病毒感染的有效药物,我们正在推出一种药物
发现活动与联合团队努力开发针对新冠肺炎的新治疗剂。我们的目标是
为了针对SARS-CoV-2的非结构蛋白16(NSP16),核糖2‘-O-甲基转移酶(2’-O-甲基转移酶)
MTase)负责病毒RNA帽-1结构的形成,这是5‘-帽的最后一步
冠状病毒。甲基化机制对病毒复制和宿主免疫逃避病毒都很重要。
承认。因此,针对5‘-封顶途径的药物是消除这种病原体毒力的理想药物。
SARS-CoV-2的nsp16/nsp10蛋白复合体的X射线晶体结构最近得到了解析,
与SARS-CoV nsp16/nsp10复合结构有很大的相似性。这些产品的可用性
高分辨结构为nsp16抑制剂的筛选和设计提供了重要的结构基础。在……里面
在这个项目中,我们将结合计算机辅助的电子筛查、灵敏的生化分析和抗病毒细胞
检测以确定有效的nsp16抑制剂来对抗这种冠状病毒。我们将开展以结构为基础的高增长
通过虚拟筛选快速发现有效的nsp16 2‘-O-MTase抑制剂。最热门的放映
HITS将接受针对SARS-COV-2重组nsp16酶的生化筛选。经过验证
NSP16 2‘-O-MTase抑制剂将被测试对SARS-CoV2毒株的抗病毒活性。成就
这场药物发现运动的目的是产生一种对抗存在主义的实验性治疗的新途径
通过抑制冠状病毒的5‘端封顶途径,新冠肺炎大流行。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Y. George Zheng其他文献
Y. George Zheng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Y. George Zheng', 18)}}的其他基金
Mechanism and Inhibition of Histone Modifications
组蛋白修饰的机制和抑制
- 批准号:
10621492 - 财政年份:2023
- 资助金额:
$ 41.53万 - 项目类别:
Mechanism and Inhibition of Protein Arginine Methylation
蛋白质精氨酸甲基化的机制及抑制
- 批准号:
10079491 - 财政年份:2018
- 资助金额:
$ 41.53万 - 项目类别:
Mechanism and Inhibition of Protein Arginine Methylation
蛋白质精氨酸甲基化的机制及抑制
- 批准号:
10392637 - 财政年份:2018
- 资助金额:
$ 41.53万 - 项目类别:
Chemical Approaches to Protein Arginine Methylation
蛋白质精氨酸甲基化的化学方法
- 批准号:
8528619 - 财政年份:2010
- 资助金额:
$ 41.53万 - 项目类别:
Chemical Approaches to Protein Arginine Methylation
蛋白质精氨酸甲基化的化学方法
- 批准号:
7986077 - 财政年份:2010
- 资助金额:
$ 41.53万 - 项目类别:
Chemical Approaches to Protein Arginine Methylation
蛋白质精氨酸甲基化的化学方法
- 批准号:
8324722 - 财政年份:2010
- 资助金额:
$ 41.53万 - 项目类别:
Chemical Approaches to Protein Arginine Methylation
蛋白质精氨酸甲基化的化学方法
- 批准号:
8136011 - 财政年份:2010
- 资助金额:
$ 41.53万 - 项目类别:
Chemical Approaches to Protein Arginine Methylation
蛋白质精氨酸甲基化的化学方法
- 批准号:
8725683 - 财政年份:2010
- 资助金额:
$ 41.53万 - 项目类别:
Chemical Approaches to Protein Arginine Methylation
蛋白质精氨酸甲基化的化学方法
- 批准号:
8693069 - 财政年份:2010
- 资助金额:
$ 41.53万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 41.53万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 41.53万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 41.53万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 41.53万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 41.53万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 41.53万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 41.53万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 41.53万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 41.53万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 41.53万 - 项目类别:
Continuing Grant